Lower US sales of gRevlimid are a major drag for Dr. Reddy’s, Zydus, Aurobindo, and Cipla. (Photo Source: Freepik) Show Quick Read Summary is AI Generated. Newsroom Reviewed

Sector Overview – A Slow Quarter Ahead

Brokerages expect soft growth in Q2FY26 for pharma companies as waning gRevlimid sales, a weak acute season in India, and GST-related de-stocking weigh on growth.

Revenue growth is projected between 7–10% YoY, while earnings may rise only 4–5%, reflecting margin pressure.

Key Headwinds

Fading gRevlimid Opportunity: Lower US sales of gRevlimid are a major drag for Dr. Reddy’s, Zydus, Aurobindo, and Cipla.

GST Impact in India: Channel de-stocking in September 2025 post-GST revision hit billing for 15–20 days.

Weak Acute Season: Slower demand for acute therapies furthe

See Full Page